华兰疫苗(301207.SZ)：冻干b型流感嗜血杆菌结合疫苗获得药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of its Hib vaccine, which targets Haemophilus influenzae type b, a major pathogen causing acute lower respiratory infections in children [1] Group 1: Vaccine Development - The Hib vaccine is developed using purified Hib capsular polysaccharide combined with tetanus toxoid protein, and it is expected to induce an immune response against Hib, providing protection to the vaccinated individuals [1] - The company is also developing a combination vaccine based on the DTP (Diphtheria, Tetanus, Pertussis) framework, with the Hib vaccine as one of its components [1] Group 2: Clinical Trial and Regulatory Process - The Hib vaccine, as an unapproved single vaccine, requires the accumulation of clinical data to complete its registration application for market approval [1] - Successful registration of the Hib single vaccine will support future registration applications for the combination vaccine based on the DTP framework [1]